CN103468743A - 一种新型狂犬病疫苗及其制备方法 - Google Patents
一种新型狂犬病疫苗及其制备方法 Download PDFInfo
- Publication number
- CN103468743A CN103468743A CN2013103629218A CN201310362921A CN103468743A CN 103468743 A CN103468743 A CN 103468743A CN 2013103629218 A CN2013103629218 A CN 2013103629218A CN 201310362921 A CN201310362921 A CN 201310362921A CN 103468743 A CN103468743 A CN 103468743A
- Authority
- CN
- China
- Prior art keywords
- carrier
- rabies vaccine
- genome
- rabies
- adc68
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960003127 rabies vaccine Drugs 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 241000701161 unidentified adenovirus Species 0.000 claims abstract description 75
- 241000700605 Viruses Species 0.000 claims abstract description 38
- 229960005486 vaccine Drugs 0.000 claims abstract description 27
- 241000282577 Pan troglodytes Species 0.000 claims abstract description 21
- 239000012634 fragment Substances 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 23
- 108091008146 restriction endonucleases Proteins 0.000 claims description 21
- 239000013598 vector Substances 0.000 claims description 17
- 238000012360 testing method Methods 0.000 claims description 15
- 230000010076 replication Effects 0.000 claims description 13
- 239000013604 expression vector Substances 0.000 claims description 10
- 230000014509 gene expression Effects 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 239000002773 nucleotide Substances 0.000 claims description 10
- 125000003729 nucleotide group Chemical group 0.000 claims description 10
- 230000002950 deficient Effects 0.000 claims description 9
- 239000000427 antigen Substances 0.000 claims description 7
- 102000036639 antigens Human genes 0.000 claims description 7
- 108091007433 antigens Proteins 0.000 claims description 7
- 101900083372 Rabies virus Glycoprotein Proteins 0.000 claims description 6
- 230000002163 immunogen Effects 0.000 claims description 5
- 238000001890 transfection Methods 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 238000012856 packing Methods 0.000 claims description 3
- 230000009466 transformation Effects 0.000 claims description 3
- 230000005847 immunogenicity Effects 0.000 abstract description 4
- 102000004190 Enzymes Human genes 0.000 description 33
- 108090000790 Enzymes Proteins 0.000 description 33
- 239000013612 plasmid Substances 0.000 description 30
- 230000029087 digestion Effects 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 15
- 241000711798 Rabies lyssavirus Species 0.000 description 13
- 238000011156 evaluation Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 230000003472 neutralizing effect Effects 0.000 description 11
- 238000012408 PCR amplification Methods 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 8
- 206010037742 Rabies Diseases 0.000 description 7
- 238000005520 cutting process Methods 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 238000011330 nucleic acid test Methods 0.000 description 7
- 108020004705 Codon Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 5
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 5
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 5
- 229920002684 Sepharose Polymers 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000013605 shuttle vector Substances 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 102000012410 DNA Ligases Human genes 0.000 description 4
- 108010061982 DNA Ligases Proteins 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 208000010370 Adenoviridae Infections Diseases 0.000 description 2
- 206010060931 Adenovirus infection Diseases 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000000432 density-gradient centrifugation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000711841 Rabies virus ERA Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000711931 Rhabdoviridae Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 101150099105 alien gene Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- XUWPJKDMEZSVTP-LTYMHZPRSA-N kalafungina Chemical compound O=C1C2=C(O)C=CC=C2C(=O)C2=C1[C@@H](C)O[C@H]1[C@@H]2OC(=O)C1 XUWPJKDMEZSVTP-LTYMHZPRSA-N 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/205—Rhabdoviridae, e.g. rabies virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (10)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310362921.8A CN103468743B (zh) | 2013-08-19 | 2013-08-19 | 一种狂犬病疫苗及其制备方法 |
PCT/CN2014/084578 WO2015024484A1 (zh) | 2013-08-19 | 2014-08-16 | 一种新型狂犬病疫苗及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310362921.8A CN103468743B (zh) | 2013-08-19 | 2013-08-19 | 一种狂犬病疫苗及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103468743A true CN103468743A (zh) | 2013-12-25 |
CN103468743B CN103468743B (zh) | 2015-07-29 |
Family
ID=49793784
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310362921.8A Active CN103468743B (zh) | 2013-08-19 | 2013-08-19 | 一种狂犬病疫苗及其制备方法 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN103468743B (zh) |
WO (1) | WO2015024484A1 (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015024484A1 (zh) * | 2013-08-19 | 2015-02-26 | 成都远睿生物技术有限公司 | 一种新型狂犬病疫苗及其制备方法 |
CN107574175A (zh) * | 2017-09-11 | 2018-01-12 | 南方医科大学 | 一种基于重组腺病毒的表达载体及其构建方法 |
CN107686843A (zh) * | 2017-09-11 | 2018-02-13 | 南方医科大学 | 一种基于腺病毒AdC6的表达载体及其构建方法 |
CN108588038A (zh) * | 2018-04-10 | 2018-09-28 | 华中农业大学 | 一种基于糖蛋白密码子优化的狂犬病新型重组疫苗 |
CN114591922A (zh) * | 2022-03-30 | 2022-06-07 | 长睿生物技术(成都)有限公司 | 一种表达狂犬病毒g蛋白的重组黑猩猩源腺病毒及其制备方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107723279B (zh) * | 2017-10-18 | 2020-11-10 | 成都远睿生物技术有限公司 | 一种缺陷型腺病毒AdC68-GP的培养方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1518457A (zh) * | 2001-06-22 | 2004-08-04 | ��˹�ؽ��ʼ������о��� | 诱导细胞毒性免疫应答的方法和用于该方法的重组猿猴腺病毒组合物 |
WO2005123930A1 (en) * | 2004-06-21 | 2005-12-29 | Medizinische Hochschule Hannover | Lentiviral vector |
CN103154021A (zh) * | 2010-08-16 | 2013-06-12 | 威斯特解剖及生物研究所 | 通用甲型流感疫苗 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103937835A (zh) * | 2013-08-19 | 2014-07-23 | 中国科学院上海巴斯德研究所 | 一种基于腺病毒AdC68的表达载体及其构建方法 |
CN103468743B (zh) * | 2013-08-19 | 2015-07-29 | 中国科学院上海巴斯德研究所 | 一种狂犬病疫苗及其制备方法 |
-
2013
- 2013-08-19 CN CN201310362921.8A patent/CN103468743B/zh active Active
-
2014
- 2014-08-16 WO PCT/CN2014/084578 patent/WO2015024484A1/zh active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1518457A (zh) * | 2001-06-22 | 2004-08-04 | ��˹�ؽ��ʼ������о��� | 诱导细胞毒性免疫应答的方法和用于该方法的重组猿猴腺病毒组合物 |
WO2005123930A1 (en) * | 2004-06-21 | 2005-12-29 | Medizinische Hochschule Hannover | Lentiviral vector |
CN103154021A (zh) * | 2010-08-16 | 2013-06-12 | 威斯特解剖及生物研究所 | 通用甲型流感疫苗 |
Non-Patent Citations (5)
Title |
---|
DONGMING ZHOU, ET AL.: "A Universal Influenza A Vaccine Based on Adenovirus Expressing Matrix-2 Ectodomain and Nucleoprotein Protects Mice From Lethal Challenge", 《MOLECULAR THERAPY》 * |
GEUE,L., ET AL.: "GenBank accession number: ABN11294.1", 《GENBANK》 * |
STEVEN F. FARINA, ET AL.: "Replication-Defective Vector Based on a Chimpanzee Adenovirus", 《JOURNAL OF VIROLOGY》 * |
ZHIQUAN XIANG, ET AL.: "Mucosally Delivered E1-Deleted Adenoviral Vaccine Carriers Induce Transgene Product-Specific Antibody Responses in Neonatal Mice", 《THE JOURNAL OF IMMUNOLOGY》 * |
ZHIQUAN XIANG, ET AL.: "Novel, Chimpanzee Serotype 68-Based Adenoviral Vaccine Carrier for Induction of Antibodies to a Transgene Product", 《JOURNAL OF VIROLOGY》 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015024484A1 (zh) * | 2013-08-19 | 2015-02-26 | 成都远睿生物技术有限公司 | 一种新型狂犬病疫苗及其制备方法 |
CN107574175A (zh) * | 2017-09-11 | 2018-01-12 | 南方医科大学 | 一种基于重组腺病毒的表达载体及其构建方法 |
CN107686843A (zh) * | 2017-09-11 | 2018-02-13 | 南方医科大学 | 一种基于腺病毒AdC6的表达载体及其构建方法 |
CN108588038A (zh) * | 2018-04-10 | 2018-09-28 | 华中农业大学 | 一种基于糖蛋白密码子优化的狂犬病新型重组疫苗 |
CN114591922A (zh) * | 2022-03-30 | 2022-06-07 | 长睿生物技术(成都)有限公司 | 一种表达狂犬病毒g蛋白的重组黑猩猩源腺病毒及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103468743B (zh) | 2015-07-29 |
WO2015024484A1 (zh) | 2015-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111218459B (zh) | 一种以人复制缺陷腺病毒为载体的重组新型冠状病毒疫苗 | |
CN103468743B (zh) | 一种狂犬病疫苗及其制备方法 | |
US11142551B2 (en) | Adenovirus and uses thereof | |
CN107432930B (zh) | 一种i群4型禽腺病毒dna疫苗及其制备方法和应用 | |
CN103923943B (zh) | 一种基于腺病毒AdC7的表达载体及其构建方法 | |
US20210317476A1 (en) | Fowl adenovirus 9 (fadv-9) vector system and associated methods | |
CN103937835A (zh) | 一种基于腺病毒AdC68的表达载体及其构建方法 | |
Abrams et al. | Sequential deletion of genes from the African swine fever virus genome using the cre/loxP recombination system | |
MXPA01010273A (es) | Novedosos herpesvirus recombinantes y mutantes. | |
CN110951778A (zh) | 犬瘟热病毒CDV-3株感染性cDNA克隆及其构建方法和应用 | |
JP2008228658A (ja) | 新規なプロモーター、これを有する組み換え七面鳥ヘルペスウイルス、及びこれを利用した家禽用ワクチン | |
CN112430625B (zh) | 含有变异猪伪狂犬病病毒gD蛋白基因的重组腺相关病毒转移载体、病毒及其制备和应用 | |
CN106497893A (zh) | 表达H7N9亚型禽流感病毒嵌合型血凝素蛋白的重组火鸡疱疹病毒株rHMW及构建方法 | |
Sun et al. | Co-expression of Erns and E2 genes of classical swine fever virus by replication-defective recombinant adenovirus completely protects pigs against virulent challenge with classical swine fever virus | |
CN102732543B (zh) | 以粘蛋白1和生存素为靶点的肿瘤基因工程疫苗 | |
CN116640736A (zh) | 重组人4型腺病毒载体的SARS-CoV-2疫苗候选株的构建及其应用 | |
Guo et al. | Recombinant adenovirus expression of FMDV P1-2A and 3C protein and its immune response in mice | |
van den Akker et al. | Environmental risk assessment of replication competent viral vectors applied in clinical trials: potential effects of inserted sequences | |
CN104195156A (zh) | 一种独立表达双基因的伪狂犬病毒通用转移载体及其构建方法和应用 | |
CN117025675B (zh) | 一种提高Admax重组腺病毒包装系统的外源基因表达量的方法及应用 | |
CN117511968B (zh) | 表达SARS-CoV-2的S、E和M蛋白的重组金丝雀痘病毒及其构建方法和应用 | |
CN117070560A (zh) | 牛疱疹病毒1型Us9基因缺失疫苗株的构建及应用 | |
CN117384965A (zh) | 牛结节性皮肤病病毒tk基因缺失毒株lsdv-△tk的构建方法 | |
CN117187304A (zh) | 一种表达PCV2 Cap蛋白的重组伪狂犬病毒及制备方法和应用 | |
EA044526B1 (ru) | Аденовирус и пути его применения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220330 Address after: No. 411, Hefei Road, Huangpu District, Shanghai 200025 Patentee after: INSTITUT PASTEUR OF SHANGHAI, CHINESE ACADEMY OF SCIENCES Patentee after: Changrui Biotechnology (Chengdu) Co.,Ltd. Address before: No. 411, Hefei Road, Huangpu District, Shanghai 200025 Patentee before: INSTITUT PASTEUR OF SHANGHAI, CHINESE ACADEMY OF SCIENCES Patentee before: CHENGDU YUANRUI BIOTECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CP03 | Change of name, title or address |
Address after: No. 411, Hefei Road, Huangpu District, Shanghai 200025 Patentee after: Shanghai Institute of Immunology and Infection, Chinese Academy of Sciences Patentee after: Changrui Biotechnology (Chengdu) Co.,Ltd. Address before: No. 411, Hefei Road, Huangpu District, Shanghai 200025 Patentee before: INSTITUT PASTEUR OF SHANGHAI, CHINESE ACADEMY OF SCIENCES Patentee before: Changrui Biotechnology (Chengdu) Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240522 Address after: 610213 Chengdu Tianfu international biological city, Chengdu, Sichuan (No. 18, Section 2, biological city middle road, Shuangliu District) Patentee after: Changrui Biotechnology (Chengdu) Co.,Ltd. Country or region after: China Address before: No. 411, Hefei Road, Huangpu District, Shanghai 200025 Patentee before: Shanghai Institute of Immunology and Infection, Chinese Academy of Sciences Country or region before: China Patentee before: Changrui Biotechnology (Chengdu) Co.,Ltd. |